Haemophilia occurs in every part of the world. Unfortunately, it is estimated that only 25 per cent of people living with a bleeding disorder currently have access to adequate treatment. Sobi and Sanofi are working to change this.

The lack of access to adequate care and treatment in developing countries is rightly described by the World Federation of Hemophilia (WFH) as an urgent and important public health challenge, one where we feel is important to act.

Every person with haemophilia should have an equal right to treatment that can liberate their lives and lead to a better tomorrow. But people in different countries face different challenges. So we are working actively to find ways to provide sustainable treatment for as many people with haemophilia as possible. Our aim is the same in each country: to provide timely and sustainable access to transformative treatment for every person with haemophilia.

Clotting factor replacement therapy is seen as the standard of care for people with haemophilia. To help make treatment available to more people in countries where it is often unavailable or unreliable, we committed to donate 1 billion international units (IUs) of extended half-life recombinant factor for use in developing countries over ten years. The first 500 million IUs have been earmarked and distributed through the WFH Humanitarian Aid Program.

We are also supporting the WFH initiative with logistics and education to ensure help reaches the people who need it most.

The Humanitarian Aid Program is making a real difference, reaching thousands more people in around 40 countries. As well as being able to treat acute bleeds, hospitals and healthcare professionals in target countries know they have reliable supply. This allows them to carry out thousands of limb- and life-saving operations, and to provide prophylactic treatment which helps protect against crippling joint damage and life-threatening bleeds. The number of children on prophylaxis nearly doubled in the three years to 2018. Visit the WFH website for more information on the impact the programme is making.

We see access to safe, effective and reliable treatment for people wherever they are as a vital shared responsibility for all of society. We and Sanofi hope that our 10-year, 1 million IU commitment will: 

  • Enable people with haemophilia in more countries to have a better chance of reliably accessing modern treatment
     
  • Make extended half-life technology for treating haemophilia available to people who need it
    • Having access to extended half-life treatment can be even more important for people in developing countries, where it is often a long journey to the nearest treatment centre, and where local infrastructure and transport is less developed.
       
  • Allow for predictability and reliability of supply
    • With secure, reliable supply, treating physicians can plan effective treatment regimens for those under their care, increasing the chances of people with haemophilia receiving more sustained treatment. Treaters in countries where supply of treatment has traditionally been patchy or unreliable have historically triaged patients and withheld limited supplies for emergency cases.
       
  • Provide in-date product with the same shelf life as commercial material, ensuring product activity
    • We increased production capacity to enable us to set aside a part of our regular manufactured product specifically for this donation. Our goal is to supply treatment with the same shelf life to the programme as for any commercial market.
    • Providing medicines with the same shelf-life no matter where people are in the world will reduce the chance of people being treated with out-of-date or expired products.
       
  • Give people with haemophilia the chance to access the latest technological treatment options.
    • Extended half-life factors are the standard of care in several developed countries. Advances in care should not be reserved for one group of people. We are committed to do what we can to support the best outcomes for people with haemophilia, no matter where they live or their ability to pay for treatment.

The film below looks at the impact of the humanitarian aid donation.